If you have been waiting for the outcome of the appeals from Jagot J’s decision to revoke 3 of AstraZeneca’s patents relating to rosuvastatin and the treatment of hypercholesterolemia
- one of the extremely rare 5 member Full Benches of the Federal Court –
the decision is out and the patents are still invalid.
Jessup J agreed with Besanko, Foster, Yates and Nicholas JJ, but delivered separate reasons on the question of obviousness.
At 180 pages, further comment will have to wait.
AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99
